JARID2

Across TCGA pan-cancer cohorts, JARID2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated JARID2 data layer compared with 26 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher JARID2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated JARID2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, HNSC, and GBM are the cancer types where JARID2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.876	0.467	.004	29	view →
HNSC	DFS	Quartile	III,IV	0.752	0.433	.004	6	view →
GBM	OS	Median	All	0.988	0.766	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

JARID2–LSCC (DFS)

Open the LSCC breakdown →